Stay updated on Pembrolizumab in MM Residual Disease Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in MM Residual Disease Clinical Trial page.

Latest updates to the Pembrolizumab in MM Residual Disease Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check16 days agoChange DetectedThe page has undergone significant updates, including the removal of detailed descriptions of a clinical trial for MK-3475 in Multiple Myeloma, while retaining the drug's name and the revision number. The focus has shifted from specific trial details to a more general mention of the drug and its context.SummaryDifference63%
- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check38 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check66 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1.0%
- Check88 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.SummaryDifference1.0%
Stay in the know with updates to Pembrolizumab in MM Residual Disease Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in MM Residual Disease Clinical Trial page.